Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sihuan Pharma Gains OK for Opioid Inhibitor

publication date: Jan 16, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sihuan Pharmaceutical Holdings received SFDA approval to begin producing Nalmefene Hydrochloride, a generic version of the “next generation” opioid receptor inhibitor Naloxone/Naltrexone. Nalmefene hydrochloride is used to counteract opioid overdose and to protect from drug relapse. Sihuan said the drug is also effective for treating heart failure, spinal cord injuries and cerebral protection following stroke. Sihuan Pharma specializes in cardio-cerebral vascular drugs. More details....

Stock Symbol: (HK: 0460)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors